Skip to main content

IL-17

      My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
      RT @swethaann23: ⭐️Prevalent drug utilization was not related to enthesitis activity
      ⭐️Prevalent use of cDMARDs

      swethaann23 swethaann23

      3 years 7 months ago
      ⭐️Prevalent drug utilization was not related to enthesitis activity ⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i ⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
      RT @Janetbirdope: #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #usteki

      Janet Pope Janetbirdope

      3 years 7 months ago
      #Guselkimab Better than #ustekinumab for skin& MSK. #Ixekizumab beat ustekinumab for skin. #ustekinumab loses throne in #psoriasis and #psoriatic arthritis except maybe if concomitant inflammatory bowel disease post TNFi? Rapidly evolving PsA Rx. Abst#1773 #ACR21 @RheumNow https://t.co/Dkf2DFFsSK
      RT @Janetbirdope: IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More

      Janet Pope Janetbirdope

      3 years 7 months ago
      IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
      RT @KDAO2011: IL-17i for GCA? TitAIN study met all endpoints!
      phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PC

      TheDaoIndex KDAO2011

      3 years 7 months ago
      IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
      RT @uptoTate: Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs

      Dr. Rachel Tate uptoTate

      3 years 7 months ago
      Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki
      RT @DrPetryna: Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PD

      Olga Petryna DrPetryna

      3 years 7 months ago
      Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PDE4 since 2018 guideline update: anti-IL17 compared to 2018 or earlier (30% vs 3.5% p< 0.001);anti-PDE4 (40% vs 11.5% p< 0.012). Meds SEs& prevention of joint damage important for pts
      RT @doctorRBC: After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts
      ⭐️TNFi most common

      Robert B Chao, MD doctorRBC

      3 years 7 months ago
      After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts ⭐️TNFi most common tx ⭐️28% pts not on any tx⭐️ #ACR21 @RheumNow Abs#1810 https://t.co/7Rmirfm3nK https://t.co/0Ui9pq5uyo
      RT @doctorRBC: No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i
      ⭐️Age,

      Robert B Chao, MD doctorRBC

      3 years 7 months ago
      No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo
      The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 
      RT @RHEUMarampa: This post hoc analysis of SPIRIT 1&amp;2 in #psoriaticarthritis pts w/ symptoms indicative of axial inv

      sheila RHEUMarampa

      3 years 7 months ago
      This post hoc analysis of SPIRIT 1&2 in #psoriaticarthritis pts w/ symptoms indicative of axial involvement showed that Ixekizumab reduced axial symptoms and improved QoL at wks 16 & 24. Reassuring data. @RheumNow #ACR21 abs1347 https://t.co/aFixZdiEyx
      RT @synovialjoints: AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women

      Dr. Antoni Chan synovialjoints

      3 years 7 months ago
      AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0
      RT @swethaann23: Study on enthesitis response to biologic Rx

      ⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compar

      swethaann23 swethaann23

      3 years 7 months ago
      Study on enthesitis response to biologic Rx ⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab ⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab 🔰Superiority of TNFi versus secukinumab in regards to active enthesitis Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ
      ×